Drug Therapy for Stroke Prevention
33%
off

Drug Therapy for Stroke Prevention

Edited by 

Free delivery worldwide

Available. Dispatched from the UK in 3 business days
When will my order arrive?

Not expected to be delivered to the United States by Christmas Not expected to be delivered to the United States by Christmas

Description

Stroke is the third leading cause of death in the USA and UK. It is a major cause of disability among adults and is a significant factor in dementia in later life and its incidence is on the rise. This book discusses specific medications that target the blood and vasculature and how these treatments can be used to complement other therapeutic measures, such as carotid endarterectomy. It covers the pharmacological methods used to address the risk factors in stroke, the major drug discoveries of recent years--antiaggregant, antithrombotic, and anticoagulant therapies--and also long established therapies such as aspirin and warfarin. With contributions by internationally recognized experts, this is a unique single source of information on current pharmacological prevention of stroke.show more

Product details

  • Hardback | 320 pages
  • 154 x 234 x 20mm | 662.26g
  • Taylor & Francis Ltd
  • London, United Kingdom
  • English
  • 20 b&w line figures
  • 0748409343
  • 9780748409341

Table of contents

1. Stroke Prevention in 2000 J. Easton 2. Primary vs. Secondary Stroke Prevention P. Gorelick 3. Aspirin P. De Moerloose 4. Ticlopidine and Clopidogrel M. Paciaroni 5. Other Anti-platelet Agents A. Culebras 6. Dipyridamole H. Diener 7. New Antiplatelet Agents B. Weksler 8. Clinical Use of Antiplatelet Agents for Stroke Prevention G. Donnan 9. Antithrombotic Therapy Before and After Carotid Endarterectomy H. Barnett 10. Anticoagulants T. Moulin 11. Early Prevention of Stroke Recurrence M. Brown 12. Lipid Lowering Agents and Stroke Risk P. Amarenco 13. Stroke Prevention With Blood Pressure Control P. Bath 14. Antioxidants, Vitamins D. Spence 15. Estrogen Replacement L. Brass 16. Healthcare Issues, Benefits and Costs G. Hankey Gorelick, Centre for Stroke Research, USA, Babette Weksler, Cornell University, USA, Geoffrey Donnan, National Stroke Research Institute, Australia, H. Barnett, Robarts Research Institute, Canada, Martin Brown, University of London, UK, Pierre Amarenco, Hospital Lariboisere, France, Phillipe Bath, Nottingham City Hospital, UK, J. David Spence, Robarts Research Institute, Canada, Graeme Hankey, Royal Perth Hospital, Australia, H. Diener, Neurologische Uniklinik, Germany, Lawrence Brass, Yale University School of Medicine, USA, Thierry Moulin, Hospital Regional de Bescancon, Maurizio Paciaroni, University of Perugia, Italy, Antonio Culebras, VA Medical Centre, USA, Phillipe de Moerloose, HUG, Geneva.show more

About Julien Bogousslavsky

'Dr Bogousslavsky, himself one of the most prominent names in cerebrovascular disease worldwide, has put together a group of authors who are, without doubt, the world leaders in their field.' - Dr John Bamford, Neurologist and Cerebrovascular Physician.show more